Structural and mechanistic analysis of two prolyl endopeptidases: role of interdomain dynamics in catalysis and specificity.
Prolyl endopeptidases (PEPs) are a unique class of serine proteases with considerable therapeutic potential for the treatment of celiac sprue. The crystal structures of two didomain PEPs have been solved in alternative configurations, thereby providing insights into the mode of action of these enzymes. The structure of the Sphingomonas capsulata PEP, solved and refined to 1.8-A resolution, revealed an open configuration of the active site. In contrast, the inhibitor-bound PEP from Myxococcus xanthus was crystallized (1.5-A resolution) in a closed form. Comparative analysis of the two structures highlights a critical role for the domain interface in regulating interdomain dynamics and substrate specificity. Structure-based mutagenesis of the M. xanthus PEP confirms an important role for several interfacial residues. A salt bridge between Arg-572 and Asp-196/Glu-197 appears to act as a latch for opening or closing the didomain enzyme, and Arg-572 and Ile-575 may also help secure the incoming peptide substrate to the open form of the enzyme. Arg-618 and Asp-145 are responsible for anchoring the invariant proline residue in the active site of this postproline-cleaving enzyme. A model is proposed for the docking of a representative substrate PQPQLPYPQPQLP in the active site, where the N-terminal substrate residues interact extensively with the catalytic domain, and the C-terminal residues stretch into the propeller domain. Given the promise of the M. xanthus PEP as an oral therapeutic enzyme for treating celiac sprue, our results provide a strong foundation for further optimization of the PEP's clinically useful features.
Shan
Lu
L
Department of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.
Mathews
Irimpan I
II
Khosla
Chaitan
C
D001665:Binding Sites; D020134:Catalytic Domain; D016941:Myxococcus xanthus / Q000201:enzymology*; D000085822:Prolyl Oligopeptidases; D017433:Protein Structure, Secondary; D012697:Serine Endopeptidases / Q000737:chemistry*; D020578:Sphingomonas / Q000201:enzymology*; D013329:Structure-Activity Relationship; D013379:Substrate Specificity
D012697:Serine Endopeptidases; D000085822:Prolyl Oligopeptidases
Protein Sci. 2004 Feb;13(2):412-21
14718659
Cell Mol Life Sci. 2002 Feb;59(2):349-62
11915948
Acta Crystallogr D Biol Crystallogr. 1998 Sep 1;54(Pt 5):905-21
9757107
Eur J Pharmacol. 1991 Nov 26;205(2):157-63
1812006
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
2025413
Biochem J. 2004 Oct 15;383(Pt 2):311-8
15245330
J Biol Chem. 2001 Jan 12;276(2):1262-6
11031266
EMBO Rep. 2000 Sep;1(3):277-81
11256612
J Mol Biol. 2004 Jul 9;340(3):627-37
15210359
Biochemistry. 1991 Feb 26;30(8):2195-203
1900195
Structure. 2003 Aug;11(8):947-59
12906826
Arch Biochem Biophys. 1998 Oct 1;358(1):141-8
9750174
Biochem J. 1992 May 1;283 ( Pt 3):647-8
1590752
Am J Physiol Gastrointest Liver Physiol. 2002 Oct;283(4):G996-G1003
12223360
Curr Opin Struct Biol. 1998 Oct;8(5):606-11
9818265
J Biochem. 1991 Dec;110(6):873-8
1840588
Structure. 2000 May 15;8(5):R105-10
10801499
Adv Protein Chem. 1968;23:283-438
4882249
Biol Pharm Bull. 1997 Oct;20(10):1047-50
9353562
J Biol Chem. 1980 May 25;255(10):4786-92
6768725
J Biol Chem. 2001 Jun 1;276(22):19310-7
11278687
Acta Crystallogr A. 2003 May;59(Pt 3):228-34
12714773
J Pharmacol Exp Ther. 2005 Jan;312(1):19-26
15358813
Biochemistry. 1992 Nov 10;31(44):10769-73
1420194
J Mol Biol. 1993 Jun 20;231(4):1049-67
8515464
Cell. 1998 Jul 24;94(2):161-70
9695945
Acta Crystallogr D Biol Crystallogr. 1999 Apr;55(Pt 4):849-61
10089316
FEBS Lett. 1988 Jul 18;234(2):251-6
3292288
Science. 2002 Sep 27;297(5590):2275-9
12351792